Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research area
Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will enable researchers to make significant discoveries that enhance our understanding of diseases, with the potential to replace existing technologies in pivotal research areas.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.